2018 – Page 13 – Oral Cancer News

Should kids be required to get the HPV vaccine?

Source: www.forbes.com Author: Bruce Y. Lee If a bill recently introduced in Florida passes, the human papillomavirus (HPV) vaccine would be mandatory for adolescents attending public school in the state. Currently, the vaccine is mandatory for boys and girls in Rhode Island and just girls in Virgina and Washington, DC. (AP Photo/John Amis, File) Florida isn't kidding about low human papillomavirus (HPV) vaccination rates. If you are a kid enrolled in a Florida public school, come July 1, 2018, you may be required to get the HPV vaccine. That is if you are old enough and if a bill now being debated in the Florida state legislature ends up passing. If it gets through, Senate Bill 1558 would then become known as the "Women's Cancer Prevention Act", which is a much easier name to remember and also reflects some major benefits of the HPV vaccine. As the National Cancer Institute explains, HPV vaccine can help prevent not only cervical cancer but also many vaginal and vulvar cancers. In fact, two types of HPV (16 and 18) cause around 70% of cervical cancers. But just because you don't have a vagina, cervix, and vulva doesn't mean that you are in the clear. HPV is responsible for about 95% of anal cancers, 70% of oropharyngeal (the middle part of the throat) cancers, and 35% of penile cancers. Thus, the "Women's Cancer Prevention Act" is really a "Cancer Prevention Act." Regardless, Florida State Senator José Javier Rodríguez (D-Miami) filed this bill [...]

Oral Cancer Foundation News Team - A2018-02-13T14:05:18-07:00February, 2018|Oral Cancer News|

Living with cancer in the country: Many Wyoming residents must leave home to seek the care they need

Source: trib.com Author: Katie King Bob Overton is all too familiar with the 140-mile stretch of land between Thermopolis and Casper. He and his wife, Sherry, made the two-hour trip in their white pickup dozens of times while Bob was undergoing treatment for lymphoma in 2015. Even with the help of Alan Jackson and Martina McBride’s music, the hours still lagged, with nothing to stare at except endless grassy plains. “That trip is pretty monotonous, and it doesn’t get any better with time,” he recalled. But the couple didn’t have a choice. Their hometown of Thermopolis, population 3,009, doesn’t offer the care Bob needed. And the Overtons aren’t alone. As the least populated state in the country, Wyoming appeals to those in search of space and wilderness. But the peace and quiet comes with drawbacks: Services that urban residents may take for granted, like advanced medical care, aren’t readily available for thousands of people living in small towns and rural areas. Many of those battling cancer in Wyoming subsequently end up seeking treatment in Casper, according to Rocky Mountain Oncology’s Patient Navigator Sam Carrick. She said the center is the only medical facility in the state that offers radiation, chemotherapy and Positron emission tomography scans. Other areas may offer one or two of those services, but many prefer the convenience of a one-stop shop, she said. About 15 percent of their patients are from out-of-town, added Carrick, who is responsible for guiding all patients through the treatment process. She said [...]

Oral Cancer Foundation News Team - A2018-02-04T09:47:02-07:00February, 2018|Oral Cancer News|

Biofilms in tonsil crypts may explain HPV-related head and neck cancers

Source: www.genengnews.com Author: staff Human papilloma virus (HPV) encased in biofilms inside tonsil crypts (pictured) may explain why the roughly 5% of HPV-infected people who develop cancer of the mouth or throat are not protected by their immune systems. Tonsil crypts with HPV are shown in green; epithelial and biofilm layers are shown in red. [Katherine Rieth. M.D.] How can human papilloma virus (HPV) be prevalent in otherwise healthy people not known to carry it? A just-published study concludes that the virus may be lurking in small pockets on the surface of their tonsils. Researchers from University of Rochester Medical Center (URMC) found HPV encased in biofilms inside tonsil crypts, where HPV-related head and neck cancers often originate. HPV is shed from the tonsil during an active infection and gets trapped in the biofilm, where it may be protected from immune attack. In the crypts, the virus likely lays in wait for an opportunity to reinstate infection or invade the tonsil tissue to develop cancer. “The virus gains access to the basal layer of stratified squamous epithelium through structural breaks in the stratified epithelial superstructure,” the investigators reported in the study. “Tonsillar crypt reticulated epithelium itself has been shown to contain numerous small blood vessels and has a discontinuous basement membrane, which may facilitate this infection and reinfection process.” The URMC researchers said their finding could help prevent oropharyngeal cancers that form on the tonsils and tongue—and may explain why the roughly 5% of HPV-infected people who develop cancer [...]

Oral Cancer Foundation News Team - A2018-02-01T09:46:22-07:00February, 2018|Oral Cancer News|

CDHA Urges Hygienists to Remind Patients of Oral Cancer Screening

Author: Canadian Dental Hygienists Association Date: January 29, 2018 Source: https://www.oralhealthgroup.com World Cancer Day (February 4) is a perfect time for dental hygienists across Canada to remind the public of the importance of regular oral cancer screenings, not only during dental appointments, but also now at home. The Canadian Cancer Society projected in 2017 that 4,700 Canadians would be diagnosed with oral cavity cancer, and that 1,250 Canadians would die. In hopes of improving the long-term outcomes for people diagnosed with oral cancer, the Canadian Dental Hygienists Association (CDHA) has partnered with the Oral Cancer Foundation and the American Dental Hygienists Association on a “Check Your Mouth™” initiative to help individuals identify the early signs and symptoms of oral cavity cancers. “Dental hygienists recognize that early detection has great potential to reduce the oral cancer burden in Canada,” states Sophia Baltzis, CDHA president. “Between dental visits, which usually include an oral cancer screening, our clients can and should examine their mouths for suspicious tissue changes.” The Check Your Mouth™ campaign features an interactive website (www.checkyourmouth.org) that offers easy-to-use tools and tips for a quick visual and tactile examination of the oral cavity. Individuals can learn to self-discover the early symptoms of disease and then seek further evaluation from a dental professional if necessary. “Dental hygienists are your partners in prevention,” adds Baltzis. “We encourage all Canadians to maintain a healthy lifestyle, practice good oral hygiene habits, and spot the early signs of oral cancer. The Check Your Mouth™ website is a valuable [...]

Charlotte Parker2018-02-06T14:57:40-07:00January, 2018|Oral Cancer News|

Study Identifies Potential Cause of Hearing Loss from Cisplatin

Author: NCI Staff Date: January 26, 2018 Source: National Cancer Institute (https://www.cancer.gov/news-events) Results from a new study may explain why many patients treated with the chemotherapy drug cisplatin develop lasting hearing loss. Researchers found that, in both mice and humans, cisplatin can be found in the cochlea—the part of the inner ear that enables hearing—months and even years after treatment. By contrast, the drug is eliminated from most organs in the body within days to weeks after being administered. The study, led by researchers from the National Institute on Deafness and other Communication Disorders (NIDCD), part of the National Institutes of Health, was published November 21 in Nature Communications. Cisplatin, a platinum-based chemotherapy drug, is commonly used for the treatment of many cancers, including bladder, ovarian, and testicular cancers. But cisplatin and other similar platinum-containing drugs can damage the cochlea, leaving 40%–80% of adults, and at least 50% of children, with significant permanent hearing loss, a condition that can greatly affect quality of life. “This study starts to explain why patients who receive the drug sustain hearing loss,” said Percy Ivy, M.D., associate chief of NCI’s Investigational Drug Branch, who was not involved in the study. “This is very important, because as we come to understand how cisplatin-related hearing loss occurs, over time we may figure out a way to block it, or at least diminish its effects.” A New Approach to Researching Cisplatin-Induced Hearing Loss The new study differs from previous research because it is a comprehensive look at the pharmacokinetics, or concentration, of the [...]

Charlotte Parker2018-02-06T14:57:52-07:00January, 2018|Oral Cancer News|

NHS immunises girls but not boys against potentially deadly HPV virus because its ‘not cost-effective’

Source: www.thesun.co.uk Author: Jacob Dirnhuber Girls aged 12 to 13 are already vaccinated for free against the HPV virus, which can cause deadly tumours in the throat and mouth, but boys have to do without. Experts believe it would take £22 million a year to vaccinate every boy in Britain against the deadly disease - a fraction of the vast £148 billion NHS budget. But low overall infection rates mean that bean-counters refuse to sign off on any additional funding - condemning thousands to months of expensive, agonising cancer treatment. Cambridge University Professor Margaret Stanley blasted: "You cannot protect against these cancers by only vaccinating half the population." She told the Mail on Sunday: "Not to immunise boys is classic Treasury short-termism. You may not spend so much now, but it will cost far more years later. "We are in the midst of an HPV pandemic." HPV is generally spread through genital and oral sex, and can also be transmitted by kissing - meaning that some people who contract it are virgins. Only a tiny minority of those infected go on to develop cancer, often decades after they contract the virus. An estimated 80 per cent of all adults in the UK have been infected at some point. Throat and cancer specialist Professor Christopher Nutting said: "My patients are being struck down by a preventable cancer that will affect them for the rest of their lives. "It's unfair that women are protected but men are not. The vaccine will work. [...]

Oral Cancer Foundation News Team - A2018-01-29T07:18:30-07:00January, 2018|Oral Cancer News|

New “soft” laser treatment to improve quality of life for cancer patients

Source: www.world-first.co.uk Author: staff A new "soft" laser therapy is to be used nationwide to help prevent patients undergoing treatment for neck and head cancer from suffering severe side effects. The low-level laser therapy (LLLT), or photomedicine, will help prevent patients suffering from soreness in the mouth and throat, dry mouth and swallowing problems. More than 90% of the 4,000 people a year in England and Wales who receive chemoradiotherapy for head and neck cancer experience side effects which can lead to hospital admissions and, in some cases, interrupt the course of radiotherapy. The new treatment, developed by the NHS foundation trusts of University Hospital Southampton and Newcastle Upon Tyne Hospitals, is being trialled nationwide as part of a £1.2 million study funded by the National Institute for Health Research (NIHR). One of the main complications of current treatments is oral mucositis (OM), which affects taste and speech. It causes excessive secretions of saliva, which result in nausea, vomiting and weight loss. Currently, patients are treated with a combination of painkillers and anti-sickness drugs and many require frequent hospital appointments to control their symptoms. Some also need nutritional support through nasal or stomach feeding tubes. LLLT is a drug-free treatment that stimulates damaged cells using a low energy laser beam to reduce pain and inflammation. It's more commonly used to treat musculoskeletal problems such as tendon, bone and nerve damage. Consultant clinical oncologist at Southampton General Hospital Dr Shanmugasundaram Ramkumar said the LLLT would improve quality of life for patients. [...]

Oral Cancer Foundation News Team - A2018-01-26T07:43:07-07:00January, 2018|Oral Cancer News|

Dr. Califano discusses the role of surgery in head and neck cancer

Source: www.onclive.com Author: Joseph A. Califano, MD Joseph A. Califano, MD, professor of surgery, University of California, San Diego, discusses the role of surgery in head and neck cancer. The surgeon has evolved to have a more integrative role in patient care for those with head and neck cancer. Current surgical techniques used in the treatment of head and neck cancers have greatly evolved in the last two decades. Surgery is more precise, and leaves patients with excellent function and cosmetic results by incision through natural orifices, Califano says. Robotic surgery is the cornerstone of head and neck cancer surgery, says Califano. It is effective in terms of resecting tumors of the throat, tonsils, back of the tongue, and the nasopharynx—which are hard to reach without robotic instrumentation. Califano says that the benefits of robotic surgery in this setting are that it leaves patients with excellent function, swallowing, voice, and allows for a rapid recovery.

Oral Cancer Foundation News Team - A2018-01-25T13:32:44-07:00January, 2018|Oral Cancer News|

Anti-smoking plan may kill cigarettes–and save Big Tobacco

Date: January 19, 2018 Author: Matthew Perrone Source: www.apnews.com WASHINGTON (AP) — Imagine if cigarettes were no longer addictive and smoking itself became almost obsolete; only a tiny segment of Americans still lit up. That’s the goal of an unprecedented anti-smoking plan being carefully fashioned by U.S. health officials. But the proposal from the Food and Drug Administration could have another unexpected effect: opening the door for companies to sell a new generation of alternative tobacco products, allowing the industry to survive — even thrive — for generations to come. The plan puts the FDA at the center of a long-standing debate over so-called “reduced-risk” products, such as e-cigarettes, and whether they should have a role in anti-smoking efforts, which have long focused exclusively on getting smokers to quit. “This is the single most controversial — and frankly, divisive — issue I’ve seen in my 40 years studying tobacco control policy,” said Kenneth Warner, professor emeritus at University of Michigan’s school of public health. The FDA plan is two-fold: drastically cut nicotine levels in cigarettes so that they are essentially non-addictive. For those who can’t or won’t quit, allow lower-risk products that deliver nicotine without the deadly effects of traditional cigarettes. US health officials are pushing ahead with an unprecedented plan to make cigarettes less addictive and provide lower-risk alternative products to US smokers. (Jan. 19) This month the government effort is poised to take off. The FDA is expected to soon begin what will likely be a years-long process [...]

Charlotte Parker2018-02-06T14:58:15-07:00January, 2018|Oral Cancer News|

Study provides new guidelines for assessing severity of head and neck cancers

Source: eurekalert.org Author: press release Cedars-Sinai Medical Center Cedars-Sinai investigators have developed a new, more accurate set of guidelines for assessing the severity of head and neck cancers and predicting patient survival. The new guidelines, outlined in a study recently published in the Journal of Clinical Oncology, center around counting the number of malignant lymph nodes found in each patient. "The greater the number of malignant lymph nodes, the less favorable the patients' chances of survival," said Allen S. Ho, MD. Ho is director of the Head and Neck Program at the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai and lead author of the study. "This new approach could dramatically simplify staging systems." For decades, doctors have determined the stage and predicted the progression of head and neck cancers based primarily on nodal size, location and how far the cancer has spread beyond the lymph nodes, but they have given less importance to the number of cancerous nodes. As a result, staging and treatment recommendations, based on current national guidelines, "are the same whether a patient has two or 20 positive lymph nodes," said Zachary S. Zumsteg, MD, assistant professor of Radiation Oncology at Cedars-Sinai and the study's senior author. With the new system, based on the number of cancerous lymph nodes, patients are separated into similarly sized groups with distinct outcomes, Zumsteg said. "Our study demonstrated a better way to assess cancer severity, which will improve our ability to predict outcomes and give patients more personalized treatment." The Cedars-Sinai [...]

Oral Cancer Foundation News Team - A2018-01-24T09:24:42-07:00January, 2018|Oral Cancer News|